This
time last year, at the 17th Conference on Retroviruses and Opportunistic Infections (CROI), Dr Moupali
Das of the San Francisco Department of Public Health presented
evidence to show that the city’s intensive testing and treatment policy was
beginning to result in a declining HIV infection rate there. Similar
evidence was presented from the province of British Columbia in Canada.
The evidence presented still leaves some questions unanswered, however.
- Is the reduction in viral load in the HIV-positive population (the 'community viral load' or CVL) really the cause of the decreased level of
diagnoses seen in San Francisco in the last few years, or is it due to the
success of prevention campaigns and reductions in risky behaviour?
- Do reduced
diagnoses really indicate reduced incidence of infection?
- Is reducing the average
viral load of diagnosed people a good indicator of the average infectiousness of people with HIV in the community
– or do high viral loads in the minority who remain undiagnosed make this an
unreliable indicator?
The
answers to these questions are crucial as the future direction of HIV
prevention policy may depend on them, in particular whether to concentrate on
suppressing viral load or on behaviour change as the mainspring of prevention.
Update from San Francisco
Dr
Das presented more evidence from San Francisco to show a strong correlation between reductions in
community viral load and the falling number of HIV diagnoses. The most recent
CVL, defined as the average viral load of all HIV positive people being seen
for care in the city, went down from approximately 25,000 copies/ml in 2004 to 10,000 copies/ml in 2009. Over
the same time, new diagnoses of HIV decreased from 820 in 2004 to 500 in 2009.
For
CVL to decrease, a number of other things have to happen first, in a ‘cascade’
of events. Firstly, the frequency of testing in the at-risk population must
increase; this must result in a lower proportion of undiagnosed cases; those
diagnosed must be linked to care, and the majority must start treatment; and
the time between diagnosis and viral suppression must reduce.
Dr
Das said all these indicators were strongly correlated. The average time from
diagnosis to the start of treatment shrank from twelve months in 2004 to two
months in 2009. The time between diagnosis and achieving an undetectable viral
load went down from nearly three years in 2004 to eight months in 2009; and the
percentage with an undetectable viral load within a year of diagnosis increased
from 26% in 2004 to 82% in 2008.
The average
CD4 count at the start of treatment increased from 357 to 445 in the two years between 2007 and 2009, but CD4 count at diagnosis "remains stubbornly between 400 and 450", Dr Das commented.
Interestingly, therefore, the reduction in CVL appears not to be due to
increasing the frequency of HIV testing – at least so far. Rather, it
appears to have been mainly driven by San Francisco's decision to
abandon CD4 count as a criterion for starting therapy and to offer
treatment to everyone diagnosed.
All
these trends were highly correlated and the correlation was highly
statistically significant (p=<0.001). Nonetheless,
it is notable that Dr Das did not include an estimate of trends in actual
incidence (the number of people actually infected in a year). This is because without using a reliable assay that can actually estimate time of infection, the
possibility remains that a current fall in diagnoses actually reflects falls in
HIV transmissions, caused by improvements in risk behaviour, up to a decade ago.
Treatment-as-prevention models
Several
modelling studies analysed the degree to which different interventions would
result in a reduction in HIV infections. One based on the HIV epidemic in the
Netherlands (van Sighem) calculated the result of three different
interventions: a 40% reduction in risk behaviour, reducing the time from
infection to diagnosis from the current 2.4 years to one year, or treating
everyone immediately at diagnosis.
In
the Netherlands, far from infections decreasing, the number of infections
diagnosed per year increased from 382 in 2000 to 840 in 2008 and would increase
to 1462 infections a year with no interventions.
A
40% reduction in risk behaviour would reduce the true number of infections (not
diagnoses) in 2019 to 138. Reducing time to diagnosis to one year would reduce
the number to 629. But immediate treatment, although it would result in a
rapid decrease in infections, would not produce a sustained decline in
infections and they would be back up to 914 a year by 2019.
The decline in
infections in British Columbia has, in recent years, been strongly tied to a
successful initiative to reduce undiagnosed infections in injecting drug
users. A study from Baltimore (Kirk) found that diagnosis and treatment was
having a similar impact on injecting drug users there. In recent years, it
found, HIV incidence decreased by 68% for each tenfold decline in the community
viral load in this population. The risk of an HIV-negative member of this
population becoming infected with HIV decreased by 5% for each 1% increase in
the proportion of HIV-positive members of the population on HIV treatment.
A
mathematical model (Lima) by the British Columbia team, however, finds that in
the case of gay men, universal treatment and reducing community viral load will
not reduce onward transmissions by the same extent. This is because gay men
will still be infectious in the first six months on treatment, a minority will
remain so and the impact of treatment on reducing new infections is extremely
dependent on the number of sexual partners people have. This is especially the
case if people are closely connected in sexual networks.
“While
the power of HAART to decrease infection remains strong and substantial, these
results show that other interventions coupled with full HAART coverage of all
medically eligible HIV-infected individuals can provide a tremendous chance to
lessen the epidemic among MSM,” say the researchers.
Abstracts and webcast
You can view the abstracts from this research on the official conference
website:
Abstract 1022 and the PDF of the poster: http://www.retroconference.org/2011/Abstracts/41808.htm
Abstract 483: http://www.retroconference.org/2011/Abstracts/40183.htm
Abstract 484: http://www.retroconference.org/2011/Abstracts/42134.htm
Abstract 486: http://www.retroconference.org/2011/Abstracts/41978.htm
You can also view a webcast of the themed discussion Community
Viral Load on the official conference website.
We rely on donations to continue our work to help people with HIV;
support us today at: www.aidsmap.com/donate